Omeza warned over poor man­u­fac­tur­ing con­di­tions; MiMedx in FDA talks over Ax­iofill re­clas­si­fi­ca­tion

Skin health com­pa­ny Omeza was is­sued an FDA warn­ing let­ter af­ter sev­er­al man­u­fac­tur­ing is­sues were un­cov­ered at its site in Sara­so­ta, FL. Mean­while, MiMedx is in dis­cus­sions with the agency on the po­ten­tial re­clas­si­fi­ca­tion of its pla­cen­tal-de­rived tis­sue prod­uct Ax­iofill.

The warn­ing let­ter to Omeza, post­ed on the FDA web­site on Dec. 26, was trig­gered by an in­spec­tion be­tween Ju­ly 24 and 28, with the com­pa­ny re­spond­ing on Aug. 17. How­ev­er, ac­cord­ing to the warn­ing let­ter dat­ed Dec. 12, the agency deemed the com­pa­ny’s re­sponse as “in­ad­e­quate.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER